Delving into the Latest Updates on Carrier Clinic, Inc. with Synapse

Overview

The purpose of this research study is to determine whether Nexalin Trans-Cranial Electrical Stimulation (TES) is an effective treatment for depression among patients who are candidates for ECT. A secondary aim to assess whether Nexalin can be used as an alternative to ECT. Although Nexalin has been approved for use in the US, using Nexalin to treat depression in this way is investigational and experimental. If Nexalin is found to be an alternative to ECT, it could offer a safer treatment for depression with less side-effects and a lower cost.
!!! NOTE !!! Post Script / Post Study. The ECT arm (profiling subjects as ECT accepters vs. rejecters) was dropped owing to site objections by referring clinicians. Accordingly, the study was framed as a simple comparison between TES and SHAM TES.

Start Date01 Sep 2017

Sponsor / Collaborator

University of Pennsylvania

[+1]

100 Clinical Results associated with Carrier Clinic, Inc.

Login to view more data

0 Patents (Medical) associated with Carrier Clinic, Inc.

Login to view more data

13

Literatures (Medical) associated with Carrier Clinic, Inc.

26 Oct 2022·mBio

Genomic Epidemiology and Serology Associated with a SARS-CoV-2 R.1 Variant Outbreak in New Jersey

Article

Author: Chen, Liang ; Wang, Maple ; Composto, Kaelea ; Oschwald, Dayna M. ; Mathema, Barun ; Luo, Yang ; Maniatis, Tom ; Fennessey, Samantha ; Wang, Pengfei ; Mediavilla, Jose R. ; Toole, Patricia ; Kreiswirth, Barry N. ; Kramer, Yael ; Wilson, Nancy ; Zhao, Yanan ; Zuckerman, Jerry ; Chow, Kar Fai ; Zody, Michael C. ; Liu, Lihong ; Ho, David D. ; Lee, Annie ; Germer, Soren ; Cunningham, Marcus H. ; Perlin, David S. ; Iketani, Sho

The neutralizing capacities of monoclonal antibodies used to treat COVID-19 and of those recovered from previously infected and vaccinated individuals against SARS-CoV-2 variants of concern (VOCs) remain important questions. We report on a nosocomial outbreak caused by a SARS-CoV-2 R.1 variant harboring an E484K mutation among 81 unvaccinated inpatients and health care professionals.

01 Jul 2008·Behavioral healthcare

Partnering for a friendlier environment.

Article

Author: Steel, Heather W

01 Jul 2005·Expert Opinion on Drug SafetyQ3 · MEDICINE

Higher than Physician’s Desk Reference (US) doses on atypical antipsychotics

Q3 · MEDICINE

Review

Author: Goodnick, Paul J

The Physician's Desk Reference (PDR) was established to provide for the practicing of a complete listing of all medications with the FDA-approved labelling, including dosage recommendations. Perhaps in order to maximise individual usage of medications, pharmaceutical companies have frequently targeted lowest possible doses for FDA approval. However, many patients with a variety of illnesses due to resistance and/or multiple illnesses, may need higher than these dose ranges to maximise therapeutic response. In terms of regularly prescribed atypical antipsychotics released over the past 10 years, only risperidone initially obtained approval for a dose for psychosis (16 mg) higher than that suggested currently (maximum of 8 mg). The dose that was approved for mania was lower: a maximum of 6 mg. The others: respectfully, olanzapine (schizophrenia: 15 mg, mania: 20 mg), quetiapine (schizophrenia: 750 mg; mania: 800 mg), ziprasidone (schizophrenia and mania: 160 mg) and aripiprazole (schizophrenia and mania: 30 mg) obtained approvals for psychosis that may limit adverse events but, at the same time, limit benefits. Other data from various sources (double-blind trials, open-label trials, reviews and case reports) have found safety and/or efficacy for the following maximum doses: olanzapine (40 mg), quetiapine (1600 mg), ziprasidone (320 mg) and aripiprazole (75 mg). Reports above those doses are included, but either are insufficient in numbers or bring up questions on safety. In many situations, feared increase in adverse events were not magnified by use of higher doses.

100 Deals associated with Carrier Clinic, Inc.

Login to view more data

100 Translational Medicine associated with Carrier Clinic, Inc.

Login to view more data